共 121 条
[1]
Gaynes R(2005)Overview of nosocomial infections caused by gram-negative bacilli Clin Infect Dis 41 848-854
[2]
Edwards JR(2020)Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017 N Engl J Med 382 1309-19
[3]
Jernigan JA(2006)Tigecycline: a critical analysis Clin Infect Dis 43 518-524
[4]
Hatfield KM(2005)Tigecycline Drugs 65 2623-35
[5]
Wolford H(2020)Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis Adv Ther 37 1049-1064
[6]
Stein GE(2022)Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa) Clin Infect Dis 75 187-212
[7]
Craig WA(2022)Drug use investigation on the safety and efficacy of tigecycline in Japan (all-case post-marketing surveillance) J Infect Chemother 28 866-874
[8]
Frampton JE(2010)Severe coagulation disorder with hypofibrinogenemia associated with the use of tigecycline Ann Hematol 89 1063-1064
[9]
Curran MP(2015)High-dose tigecycline-associated alterations in coagulation parameters in critically ill patients with severe infections Int J Antimicrob Agents 45 90-93
[10]
Zha L(2022)Coagulation dysfunction events associated with tigecycline: a real-world study from FDA adverse event reporting system (FAERS) database Thromb J 20 12-332